Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
Comparing the Efficacy of Heated Yoga and Sauna as a Treatment for Depression
Massachusetts General Hospital
Depression Disorders
Depression - Major Depressive Disorder
Depression Disorder
Depression Chronic
Depression
This project explores whether heated yoga, sauna, and a mindfulness app reduce depressive
symptoms expand
This project explores whether heated yoga, sauna, and a mindfulness app reduce depressive symptoms Type: Interventional Start Date: Sep 2025 |
|
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Massachusetts General Hospital
Alcohol Use Disorder
Cannabis Use Disorder
This is a Phase II parallel group randomized controlled trial with 294 adolescents (age:
14-21 years) with alcohol and other drug [AOD] use disorder (hereafter substance use
disorder), that compares two different active psychosocial interventions designed to
address adolescent substance use disorde1 expand
This is a Phase II parallel group randomized controlled trial with 294 adolescents (age: 14-21 years) with alcohol and other drug [AOD] use disorder (hereafter substance use disorder), that compares two different active psychosocial interventions designed to address adolescent substance use disorder. Participants are recruited from our clinical settings and the community at two sites: one in the metro Boston, Massachusetts (MA) area and the other in the metro Farmington, Connecticut (CT), area. Study aims and hypotheses are as follows: 1. To extend the evidence for the initial efficacy of Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA), which integrates 12-Step Facilitation (TSF) with Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT) relative to gold standard MET/CBT alone (N = 294). It is hypothesized that youth assigned to InTEGRA will have greater 12-step participation during and following treatment, higher abstinence rates, and fewer substance-related negative consequences. 2. Investigate the personal recovery capital (PRC) and social recovery capital (SRC) mechanisms of behavior change through which InTEGRA may confer benefits dynamically over time (e.g., PRC: motivation, self-efficacy, coping; SRC: 12-step involvement; social network changes). 3. Investigate moderators of InTEGRA's effects on outcomes across one-year follow-up (e.g., effect of age, network support for AOD use; psychiatric severity; age composition of 12-step meetings on substance use and substance-related consequences). It is hypothesized that higher network support for AOD use, abstinence motivation, and greater AOD severity, will have a better response to InTEGRA. 4. Explore barriers and facilitators to InTEGRA adoption and implementation across providers and system administrators within the context of a type I hybrid effectiveness-implementation research design. Type: Interventional Start Date: Nov 2024 |
|
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Carcinoma
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL
prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show
the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of
diagnostic scan for prostate cancer). expand
The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer). Type: Interventional Start Date: Apr 2024 |
|
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Brigham and Women's Hospital
Advanced Prostate Cancer
Metastatic Prostate Cancer
Metastatic Prostate Neuroendocrine Carcinoma
This research study is studying a positron emission tomography (PET) agent called
18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of
advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA)
expression or has neuroendocrine features1 expand
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features. The name of the study interventions are: - 18F-fluciclovine-PET/CT scan - Two research blood collections Type: Interventional Start Date: Feb 2024 |
|
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
Target ALS Foundation, Inc.
Amyotrophic Lateral Sclerosis
Movement Disorders
Degenerative Disorder
Motor Neuron Disease
The goal of the study is to generate a biorepository of longitudinal biofluids-blood
(plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and
longitudinal clinical information that are made available to the research community. To
accomplish these goals, we will enroll 800 Am1 expand
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies. Type: Observational [Patient Registry] Start Date: Jun 2021 |
|
Biomarker Development for Muscular Dystrophies
Massachusetts General Hospital
Myotonic Dystrophy
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Current methods of measuring the response to new treatments for muscular dystrophies
involve the examination of small pieces of muscle tissue called biopsies. The
investigators are interested in finding less invasive methods that reduce the need for
muscle biopsies. The purpose of this research is1 expand
Current methods of measuring the response to new treatments for muscular dystrophies involve the examination of small pieces of muscle tissue called biopsies. The investigators are interested in finding less invasive methods that reduce the need for muscle biopsies. The purpose of this research is to learn about the possibility of detecting and measuring the activity and severity of muscular dystrophies by examining a urine sample and a blood sample, and some muscles in the arms and legs using tests called ultrasound and electrical impedance myography; both tests are painless and non-invasive. The information that is gathered from this study may help to evaluate, prevent, diagnose, treat, and improve the understanding of human muscle diseases. Type: Observational Start Date: Feb 2015 |
|
Turmeric for Patients With Basal Joint Arthritis
Massachusetts General Hospital
Thumb Osteoarthritis
The aim of this study is to assess whether the use of a commercially available
nutraceutical, turmeric, is an effective option to manage pain and stiffness in patients
with basal joint arthritis. To conduct a pilot Randomized Controlled Trial evaluating the
impact of turmeric on basal joint arthrit1 expand
The aim of this study is to assess whether the use of a commercially available nutraceutical, turmeric, is an effective option to manage pain and stiffness in patients with basal joint arthritis. To conduct a pilot Randomized Controlled Trial evaluating the impact of turmeric on basal joint arthritis. Type: Interventional Start Date: Aug 2017 |
|
Foundational Programs to Combat Clinician Stress
Lancaster General Hospital
Burnout, Professional
Stress, Psychological
Stress, Physiological
Psychological Well-Being
Mind-Body Therapies
This is a prospective, randomized, controlled clinical trial in which clinicians from
University of Pennsylvania Health Systems (UPHS) including Penn Medicine- Lancaster
General Health (LGH) and Massachusetts General Hospital (MGH) are offered a well-known
program to help reduce clinician burnout:1 expand
This is a prospective, randomized, controlled clinical trial in which clinicians from University of Pennsylvania Health Systems (UPHS) including Penn Medicine- Lancaster General Health (LGH) and Massachusetts General Hospital (MGH) are offered a well-known program to help reduce clinician burnout: Sudarshan Kriya Yoga (SKY) Breathing and Sahaj Meditation Intervention. Type: Interventional Start Date: Sep 2025 |
|
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
Massachusetts General Hospital
Crohn Disease
Inflammatory Bowel Diseases
Healthy
The goal of this research is to learn how a new device called the wireless thermal
capsule (WTC) can collect thermal data to help see diseases that happen in the
gastrointestinal (GI) tract, such as Crohn's Disease. expand
The goal of this research is to learn how a new device called the wireless thermal capsule (WTC) can collect thermal data to help see diseases that happen in the gastrointestinal (GI) tract, such as Crohn's Disease. Type: Interventional Start Date: Jun 2025 |
|
Post-Market Clinical Investigation Plan- Collagen Dural Regeneration Matrix (DuraMatrix-Onlay Plus)
Collagen Matrix
Repair of Dura Mater
Monitoring the Use of Collagen Dural Regeneration Matrix (DuraMatrix-Onlay Plus) in the
Postmarket Phase. expand
Monitoring the Use of Collagen Dural Regeneration Matrix (DuraMatrix-Onlay Plus) in the Postmarket Phase. Type: Observational Start Date: Jan 2025 |
|
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Massachusetts General Hospital
Bone Marrow Transplant Complications
Hematologic Malignancy
The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is
effective at improving the quality of life in caregivers and patients treated with
hematopoietic cell transplant compared to usual care, and to identify critical
facilitators and barriers for BMT-CARE implement1 expand
The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and to identify critical facilitators and barriers for BMT-CARE implementation and adoption. Type: Interventional Start Date: Jan 2025 |
|
A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle an1
Massachusetts General Hospital
Substance Use
Harm Reduction
Adolescent Behavior
The primary goal of this study is to test the effectiveness of the iDECIDE (Drug
Education Curriculum: Intervention, Diversion, and Empowerment) curriculum, a novel drug
education and diversion program, in approximately 300 middle and high school students,
who have violated their school substance u1 expand
The primary goal of this study is to test the effectiveness of the iDECIDE (Drug Education Curriculum: Intervention, Diversion, and Empowerment) curriculum, a novel drug education and diversion program, in approximately 300 middle and high school students, who have violated their school substance use policies in the past month, as an alternative to punitive school responses for school-based substance use infractions. This randomized controlled trial will test the hypothesis that adolescents randomized to the iDECIDE curriculum will have improved substance use outcomes (i.e., knowledge, attitudes, and behavior) compared to adolescents in a waitlist control group. The outcomes of this study will measure knowledge of drug effects and brain development, perceptions of harm from substance use, willingness to quit or reduce use, and substance use behavior. Type: Interventional Start Date: Nov 2023 |
|
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Tria1
University of Cincinnati
Stroke
Stroke, Acute
Stroke, Ischemic
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute
ischemic stroke window for immediate use in clinical trials, and explore these biomarkers
in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale,
prospective dataset of clinical, tra1 expand
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window. Type: Observational Start Date: Jun 2022 |
|
The Myelin Disorders Biorepository Project
Children's Hospital of Philadelphia
Leukodystrophy
White Matter Disease
Leukoencephalopathies
4H Syndrome
Adrenoleukodystrophy
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical
data and biological samples from leukodystrophy patients worldwide to support ongoing and
future research projects. The MDBP is one of the world's largest leukodystrophy
biorepositories, having enrolled nearly 21 expand
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future. Type: Observational [Patient Registry] Start Date: Dec 2016 |
|
CAR-T Long Term Follow Up (LTFU) Study
Novartis Pharmaceuticals
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Per Health Authorities guidelines for gene therapy medicinal products that utilize
integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of
treated patients is required. The purpose of this study is to monitor all patients
exposed to CAR-T therapied for 15 years fol1 expand
Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence. Type: Interventional Start Date: Nov 2015 |
|
Imagined Acupuncture for Postoperative Pain After Spinal Surgery
Jingping Wang, MD, Ph.D.
Pain Management
The goal of this clinical trial is to evaluate whether imagined acupuncture can reduce
postoperative acute pain in adult patients undergoing spinal surgery. The main questions
it aims to answer are:
Does video-guided imagined acupuncture improve postoperative pain control?
Does the intervention r1 expand
The goal of this clinical trial is to evaluate whether imagined acupuncture can reduce postoperative acute pain in adult patients undergoing spinal surgery. The main questions it aims to answer are: Does video-guided imagined acupuncture improve postoperative pain control? Does the intervention reduce opioid consumption and improve functional recovery in the immediate postoperative period? Researchers will compare the imagined acupuncture group to the control education video group to see if imagery-based intervention leads to better pain outcomes and reduced analgesic use. Participants will: Watch a 30-minute video once daily for 7 consecutive days after surgery Complete pain and function assessments during the hospital stay and postoperative follow-up Type: Interventional Start Date: Oct 2025 |
|
Mindfulness-based Cognitive Therapy vs the Health Enhancement Program for Chronic Pain and Depressi1
Massachusetts General Hospital
Chronic Pain
Depression
The goal of this clinical trial is to pilot a randomized controlled trial comparing an
adaptation of mindfulness-based cognitive therapy to the health enhancement program for
chronic pain and depression. The main questions it aims to answer in a later fully
powered randomized controlled trial are:1 expand
The goal of this clinical trial is to pilot a randomized controlled trial comparing an adaptation of mindfulness-based cognitive therapy to the health enhancement program for chronic pain and depression. The main questions it aims to answer in a later fully powered randomized controlled trial are: - Is an adaptation of mindfulness-based cognitive therapy for older Black adults able to improve quality of life? - Will an adapted mindfulness based cognitive therapy reduce pain interference to a greater degree than a traditional health enhancement program? Type: Interventional Start Date: Sep 2025 |
|
Impact of Cognitive Behavioral Therapy on PTSD-CVD Link
Massachusetts General Hospital
Posttraumatic Stress Disorder
This is a pilot randomized controlled trial to assess the impact of a first-line
treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT)
versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this
study will test the hypothesis that CPT r1 expand
This is a pilot randomized controlled trial to assess the impact of a first-line treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT) versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this study will test the hypothesis that CPT reduces CVD risk through its effects on inflammation and autonomic function and that these changes are driven by changes in stress-related neural activity (SNA) Type: Interventional Start Date: Jul 2023 |
|
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBR1
Phanes Therapeutics
Small Cell Lung Cancer (SCLC)
Large Cell Neuroendocrine Cancer (LCNEC)
Neuroendocrine Prostate Cancer (NEPC)
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Neuroendocrine Carcinomas (NEC)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and
combination study designed to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in
combination with chemotherapy. expand
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy. Type: Interventional Start Date: Sep 2023 |
|
Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia
Massachusetts General Hospital
Avoidant/Restrictive Food Intake Disorder
Dyspepsia
Feeding and Eating Disorders
Cognitive Behavioral Therapy
Appetite Regulation
Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults
with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder
(ARFID) with weight loss. expand
Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss. Type: Interventional Start Date: Nov 2022 |
|
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Massachusetts General Hospital
Ovarian Neoplasms
Ovarian Epithelial Carcinoma
Fallopian Tube Neoplasms
High Grade Ovarian Serous Adenocarcinoma
Stage I Ovarian Cancer
The study aims to develop a test for early detection of ovarian cancer using DNA from a
growth involving the ovary found in a washing of the uterus (womb), and proteins found in
the blood. The samples of the wash and the blood will be taken before surgery. After
surgery, doctors will determine whet1 expand
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis. Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer. Type: Observational Start Date: Apr 2020 |
|
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
Massachusetts General Hospital
Bipolar Disorder
Depressive Episode
We propose to test the hypothesis that bezafibrate, a pan-PPAR agonist, may be effective
and safe for bipolar depression with the following specific aims:
Aim #1. Proof-of-Concept Safety and Tolerability Aim: To assess the safety and
tolerability of bezafibrate added to anti-manic medication for b1 expand
We propose to test the hypothesis that bezafibrate, a pan-PPAR agonist, may be effective and safe for bipolar depression with the following specific aims: Aim #1. Proof-of-Concept Safety and Tolerability Aim: To assess the safety and tolerability of bezafibrate added to anti-manic medication for bipolar depression, especially with regard to worsening manic symptoms and suicidal ideation. We will conduct a phase IIa, 8-week, open pilot trial of bezafibrate added to FDA-approved anti-manic medication in 30 participants with bipolar depression. We will monitor changes in manic symptoms (Young Mania Rating Scale), suicidal ideation, cognitive functioning specifically in attention and verbal memory, and treatment emergent adverse events (SAFTEE). We will also monitor changes in the Framingham Cardiovascular Risk Score. Aim #2. Preliminary Assessment of Efficacy: To assess the antidepressant efficacy of bezafibrate added to anti-manic medication for acute bipolar I major depressive episodes. Hypothesis: The bezafibrate group will have a statistically significant decrease in the Montgomery Asberg Rating Scale (MADRS) Scores over 8 weeks. The results of this proof-of concept phase IIa study will help us to plan a placebo-controlled randomized trial. In summary, we propose an 8-week, proof-of-concept open pilot trial of an adjunctive pan-PPAR agonist, bezafibrate, for 30 patients with an acute bipolar I major depressive episode. The study may have a profound impact on the development of a novel treatment consistent with the mitochondrial dysregulation hypothesis of bipolar disorder and, to the best of our knowledge, will be the first proof-of-concept trial to assess a pan-PPAR agonist for bipolar disorder. Type: Interventional Start Date: Jan 2018 |
|
J-Valve Transfemoral Pivotal Study
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Aortic Valve Regurgitation
Aortic Valve Disease Mixed
The primary objective of this study is to assess the safety and efficacy of the J-Valve
Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native
aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are
judged by a multi-disciplinary heart team1 expand
The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). A Cardiac Magnetic Resonance (CMR) sub-study will examine if intervention for AR translates to improved ventricular remodeling, the impact of LV remodeling on clinical outcomes and quality of life, as well as volumetric and myocardial differences between genders. Type: Interventional Start Date: Oct 2024 |
|
A Retrospective Assessment of OviTex PRS (OviTex)
Tela Bio Inc
Reconstructive Surgical Procedures
The objective of this retrospective-prospective, observational study is to evaluate the
safety profile overall and within two device types of OviTex PRS in previous pre-pectoral
or sub-pectoral implant-based breast reconstructions. expand
The objective of this retrospective-prospective, observational study is to evaluate the safety profile overall and within two device types of OviTex PRS in previous pre-pectoral or sub-pectoral implant-based breast reconstructions. Type: Observational Start Date: Sep 2022 |
|
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
Cellectis S.A.
B-cell Non-Hodgkin Lymphoma (B-NHL)
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22
administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin
Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical
activity of UCART20x22 and determine the Maximum T1 expand
First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D). Type: Interventional Start Date: Nov 2022 |